ALK and non-small cell lung carcinoma: It is used in combination with nivolumab and 2 cycles of platinum-based chemotherapy for first-line treatment of metastatic NSCLC in adults whose tumors express PD-L1 (≥1%) and have no EGFR and ALK mutations (ClinicalTrials.gov Identifier: NCT02658890).